Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9467343 | 0.94 | SIGMAR1 (0.51) | SIGMAR1 | |
| SCHEMBL9466307 | 0.94 | SIGMAR1 (0.51) | SIGMAR1 | |
| SCHEMBL9174172 | 0.90 | SIGMAR1 (0.43) | SIGMAR1HTR6 | |
| SCHEMBL9175775 | 0.85 | SIGMAR1 (0.45) | SIGMAR1 | |
| SCHEMBL9467124 | 0.84 | ALDH1A1 (0.36) | HTR6 | |
| SCHEMBL9178363 | 0.82 | SIGMAR1 (0.41) | SIGMAR1 | |
| SCHEMBL9181626 | 0.81 | PTGDR2 (0.39) | HTR6 | |
| SCHEMBL9175467 | 0.78 | SIGMAR1 (0.40) | SIGMAR1 | |
| SCHEMBL8303444 | 0.77 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL9178801 | 0.77 | CRBN (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0490772-B1 | 1,4-Disubstituted piperazines, their process of preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-07-26 | — | — | EP | claimed |
| US-5194437-A | Substituted with oxygen containing heterocycle, central nervous system disorders, neuroendocrine disorders | ADIR ET COMPAGNIE (FR) | 1993-03-16 | — | — | US | claimed |
| US-20120115778-A1 | Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2011009012-A1 | METHODS OF SUPPRESSING APPETITE BY THE ADMINISTRATION OF ANTAGONISTS OF THE SEROTONIN HTR1a or HTR2b RECEPTORS OR INHIBITORS OF TPH2 | COLUMBIA UNIVERSITY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-5194437-A | Substituted with oxygen containing heterocycle, central nervous system disorders, neuroendocrine disorders | ADIR ET COMPAGNIE (FR) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115778-A1 | Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2 | HTR1A, HTR2B, HTR2A | SIGMAR1 565/4885HTR6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.